Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
Eli Lilly slashed prices for its hugely successful ... offer discounted Zepbound has two benefits. Discounting Zepbound signals the company's commitment to bolster its supply output while ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback